Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipegfilgrastim prophylaxis in non-Hodgkin lymphoma receiving chemoimmunotherapy
ACTRN12618000055202Phase 4Not yet recruiting
- Sponsor
- Monash Health
- Start
- Feb 2018
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of lipegfilgrastim in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Monash Health. Primary endpoint: Rate of febrile neutropenia. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
lipegfilgrastim
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on ACTRN12618000055202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000055202.